Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$46.15M

FY 2025 · Annual

Net Income

-$43.44M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.12M00013K
Gross Profit(1.12M)000(13K)
Gross Margin—————
Research & Development119.62M11.76M11.71M12.34M30.75M
Selling, General & Admin49.08M2.24M1.76M42.92M15.39M
Operating Expenses168.7M14.01M13.46M55.26M46.14M
Depreciation & Amortization1.12M00013K
EBITDA(169.84M)(15.25M)(14.01M)(58.77M)(41.98M)
EBITDA Margin—————
Operating Income(169.82M)(14.01M)(13.46M)(55.26M)(46.15M)
Operating Margin—————
Interest Income1.32M005.49M0
Interest Expense0235K687K01.44M
Other Income / Expenses(1.14M)(1.48M)(1.24M)(3.51M)2.71M
Income Before Tax(170.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Pre-Tax Margin—————
Income Tax Expense1.01M0000
Net Income(171.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Net Margin—————
EPS (Basic)(63.00)(50.62)(42.09)(11.73)(2.85)
EPS (Diluted)(63.00)(50.62)(42.09)(11.73)(2.85)
Weighted Avg Shares2.73M3.33M4.52M5.01M15.27M
Weighted Avg Shares (Diluted)2.73M3.33M4.52M5.01M15.27M

KLRS Earnings Waterfall · TTM

NASDAQ:KLRS · Revenue to Net Income

Key Ratios

EPS$-2.15
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.8
P/S Ratio0.0

Analysis

$0 of revenue converted into -$44.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.15, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingOct 26, 2026

How much revenue does KLRS generate?

Kalaris Therapeutics Inc (KLRS) reported $0.00 of revenue in fiscal 2025.

Is KLRS profitable?

Kalaris Therapeutics Inc (KLRS) reported -$43.44M of net income.